Overview

* Cogent Biosciences ( COGT ) reports Q3 net loss of $80.9 mln, up from $70.6 mln in 2024

* Cash position of $390.9 mln expected to fund operations through 2027

* Upcoming PEAK and APEX trial results expected in Nov and Dec 2025

Outlook

* Cogent plans to announce PEAK trial results in November 2025

* Company expects APEX trial results in December 2025

* Cogent aims to submit NDA for bezuclastinib by year-end 2025

Result Drivers

* R&D EXPENSES - Increased R&D expenses due to ongoing clinical trials and preclinical programs

* CASH POSITION - Strong cash position expected to fund operations through 2027

* CLINICAL PROGRESS - Significant progress with upcoming trial results and regulatory submissions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$80.93

Income mln

Q3 -$83.35

Income mln

from

Operatio

ns

Q3 $83.35

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Cogent Biosciences Inc ( COGT ) is $20.50, about 20.5% above its October 31 closing price of $16.30

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)